Compare CVV & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | CLRB |
|---|---|---|
| Founded | 1982 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 24.5M |
| IPO Year | 2007 | 2008 |
| Metric | CVV | CLRB |
|---|---|---|
| Price | $3.83 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 48.0K | ★ 154.9K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.86 | N/A |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $41,128,639.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.55 | ★ N/A |
| Revenue Growth | ★ 96.27 | N/A |
| 52 Week Low | $2.96 | $1.12 |
| 52 Week High | $9.10 | $4.70 |
| Indicator | CVV | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 28.31 |
| Support Level | $3.74 | N/A |
| Resistance Level | $4.44 | $3.40 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 36.90 | 14.58 |
CVD Equipment Corp designs, develops, and manufactures a broad range of equipment used to develop and produce materials and coatings for the aerospace, compound semiconductor, semiconductor, aerospace, battery energy storage markets as well as industrial applications, and research. It currently conducts its business through two reportable segments: CVD Equipment, which designs and manufactures chemical vapor deposition, physical vapor transport and thermal process equipment; and SDC, which designs and manufactures ultra-high purity gas and chemical delivery control systems. Its target markets are aerospace & defense and industrial, microelectronics / high power electronics, and EV battery materials / energy storage.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.